

TABLE OF CONTENTS

FROM THE EDITOR

It's a new year, looking back and looking forward 15

Reflections on highlights from 2023 and impending changes in 2024, along with some acknowledgments and farewells.

Brian F. Mandell, MD, PhD

THE CLINICAL PICTURE

Conjunctival petechiae in infective endocarditis 20

A 75-year-old man presented with a 33-day history of intermittent nocturnal fevers of 39°C (102°F) and truncal rashes. The rashes appeared on the same day as the fever.

Akinori Sekizawa, MD; Ayaka Nagano, MD; Kenichi Hashimoto, MD, PhD; Yosuke Ono, MD, PhD

REVIEW

Consumer-grade wearable cardiac monitors: What they do well, and what needs work 23

The authors review common consumer-grade wearables, including the accuracy of these monitors compared with medical-grade devices, and present an approach to managing rate or rhythm abnormalities identified on at-home monitoring.

Abdilahi Mohamoud, MBBS; Joseph Jensen, MD; Kevin G. Buda, DO



EDITORIAL

Wearable cardiac monitors: Where do we stand? 31

Wearable monitors perform well as screening tools for atrial fibrillation, but questions remain: Can they help with stroke prevention, what is their role in patients with known atrial fibrillation, and how do we streamline interpretation?

Jakub Sroubek, MD, PhD

CONTINUED ON PAGE 14

Upcoming Features

- Pancreatic cysts: A review for non-gastroenterologists
- Management of venous thromboembolism in patients with active cancer



CONTINUED FROM PAGE 7

REVIEW.....

Gastric intestinal metaplasia and gastric cancer prevention: Watchful waiting 33

Malignancy develops in only a small minority of patients with gastric intestinal metaplasia. Recognition of clinical, endoscopic, and histologic features linked with cancer development is critical to identifying patients who require endoscopic surveillance.

Shrouq Khazaaleh, MD; Mohammad Alomari, MD; Mamoon Ur Rashid, MD; Daniel Castaneda, MD; Fernando J. Castro, MD

REVIEW.....

2023 Update in ambulatory general internal medicine 40

Topics reviewed include prevention of chronic kidney disease progression, diet for preventing secondary cardiovascular disease, prevention of kidney-stone recurrence, drug therapy for weight loss, and cholesterol management.

Jason T. Alexander, MD; Simran K. Singh, MD; Sachin D. Shah, MD; Brianna Lambert, MD; Jeremy P. Smith, MD

1-MINUTE CONSULT

When should we consider SGLT-2 inhibitors in patients with acute decompensated heart failure? 47

Evidence from clinical trials supports starting these medications as early as possible in patients hospitalized with acute decompensated heart failure who do not have clear contraindications to them.

Osamah Z. Badwan, MD; Lorenzo Braghieri, MD; Warren Skoza, MD; Ankit Agrawal, MD; Venu Menon, MD; W. H. Wilson Tang, MD

CURRENT DRUG THERAPY

CME MOC

Nonstatin therapy to reduce low-density lipoprotein cholesterol and improve cardiovascular outcomes 53

Several new nonstatin medications have been approved in recent years, with robust data from clinical trials supporting their use in atherosclerotic disease.

Abhayjit Singh, MD; Leslie S. Cho, MD

LETTER TO THE EDITOR.....

Late complications after allogeneic hematopoietic cell transplant 19

Pelin Batur, MD, FACP, MSCP

DEPARTMENTS

CME Calendar 6**CME/MOC Instructions 64**